Search company, investor...

Oxford Genome Sciences (UK)


Other Investors | Alive

About Oxford Genome Sciences (UK)

Oxford BioTherapeuticsis focused on the targeted treatment of cancer.

Headquarters Location

86 Milton Park Abingdon

United Kingdom

Missing: Oxford Genome Sciences (UK)'s Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Oxford Genome Sciences (UK)'s Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Oxford Genome Sciences (UK)

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oxford Genome Sciences (UK) is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Oxford Genome Sciences (UK) Frequently Asked Questions (FAQ)

  • What is Oxford Genome Sciences (UK)'s latest funding round?

    Oxford Genome Sciences (UK)'s latest funding round is Other Investors.

  • Who are the investors of Oxford Genome Sciences (UK)?

    Investors of Oxford Genome Sciences (UK) include Percipient Capital, Oxford Capital Partners, Catapult and Washington Mutual.

  • Who are Oxford Genome Sciences (UK)'s competitors?

    Competitors of Oxford Genome Sciences (UK) include Cornerstone Pharmaceuticals, Aquinox Pharmaceuticals, Bexion Pharmaceuticals, Forte Biosciences, Alligator Bioscience and 11 more.

Compare Oxford Genome Sciences (UK) to Competitors

Cylene Pharmaceuticals

Cylene Pharmaceuticals is a clinical-stage, private company developing small molecule drugs against newly validated cancer targets. Cylene has taken a position in the discovery and development of first-in-class cancer drugs that activate the p53 tumor suppressor and drugs that target the CK2 protein kinase. The Company's p53 Activator/Pol I program delivered CX-5461, a Phase I stage small molecule that activates p53 to kill cancer cells but not normal ones. Targeting Pol I provides the first path to selectively activating p53 in malignant but not normal, healthy cells. Similarly, Cylene's leadership in exploiting CK2-dependent pathways enabled the creation of the first-in-class, Phase II ready CX-4945 agent and CX-8184, the 2nd generation agent, that can serve as the drugs of choice in rational drug combinations for improved treatment outcomes against many cancer indications. Cylene's approach delivers agents that enable pharmaceutical companies to expand portfolios and extend the efficacy, lifecycle and reach of current cancer therapeutics.

Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

PNP Therapeutics

PNP Therapeutics is dedicated to the development and commercialization of a cancer treatment approach that is predicated on well-documented evidence that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.

Alligator Bioscience

Alligator Bioscience discovers and develops antibody-based immunotherapies for the treatment of cancer. Alligator Drug Discovery and Development span early research phases with lead identification up to proof of concept phase I/II clinical studies in cancer patients.

Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.


NanoMedica aims to become engaged in design,development and manufacture of dual-action therapeutics for the treatment of human cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.